Demographic and clinical characteristics of the patients with MDS or oligoblastic AML who underwent allogeneic HSCT
| Parameter* . | MDS . | Oligoblastic AML† . | Comparison between MDS and oligoblastic AML, P . |
|---|---|---|---|
| No. of patients | 374 (72%) | 145 (28%) | |
| Age, median (range) | 48 (17-67) | 47 (23-72) | NS |
| Gender (male/female) | 202/172 | 73/72 | NS |
| WHO classification | |||
| RCUD/RARS/MDS del(5q) | 38 | — | |
| RCMD | 85 | — | |
| RAEB-1 | 87 | — | |
| RAEB-2 | 164 | — | |
| Hemoglobin, g/dL, median (range) | 8.6 (5.3-13.1) | 8.7 (6.1-10.2) | NS |
| Leukocyte count, ×109/L, median (range) | 2.6 (0.3-77.2) | 2.21 (0.5-31.4) | NS |
| Absolute neutrophil count, ×109/L, median (range) | 1.1 (0.01-33.2) | 0.96 (0.1-13.2) | NS |
| Platelet count, ×109/L, median (range) | 84 (2-692) | 41 (3-319) | NS |
| Transfusion dependency‡ | 209 (56%) | 112 (77%) | .02 |
| HCT-CI§ | 266 (71%) | 96 (66%) | |
| Low | 168 (63%) | 63 (66%) | |
| Intermediate | 63 (24%) | 18 (19%) | NS |
| High | 35 (13%) | 15 (15%) | |
| IPSS risk | |||
| Low | 29 (8%) | — | <.001 |
| Intermediate-1 | 134 (36%) | — | |
| Intermediate-2 | 157 (42%) | 20 (14%) | |
| High | 54 (14%) | 125 (86%) | |
| IPSS-R risk | |||
| Low | 59 (16%) | — | <.001 |
| Intermediate | 78 (21%) | 11 (8%) | |
| High | 140 (37%) | 67 (46%) | |
| Very high | 97 (26%) | 67 (46%) |
| Parameter* . | MDS . | Oligoblastic AML† . | Comparison between MDS and oligoblastic AML, P . |
|---|---|---|---|
| No. of patients | 374 (72%) | 145 (28%) | |
| Age, median (range) | 48 (17-67) | 47 (23-72) | NS |
| Gender (male/female) | 202/172 | 73/72 | NS |
| WHO classification | |||
| RCUD/RARS/MDS del(5q) | 38 | — | |
| RCMD | 85 | — | |
| RAEB-1 | 87 | — | |
| RAEB-2 | 164 | — | |
| Hemoglobin, g/dL, median (range) | 8.6 (5.3-13.1) | 8.7 (6.1-10.2) | NS |
| Leukocyte count, ×109/L, median (range) | 2.6 (0.3-77.2) | 2.21 (0.5-31.4) | NS |
| Absolute neutrophil count, ×109/L, median (range) | 1.1 (0.01-33.2) | 0.96 (0.1-13.2) | NS |
| Platelet count, ×109/L, median (range) | 84 (2-692) | 41 (3-319) | NS |
| Transfusion dependency‡ | 209 (56%) | 112 (77%) | .02 |
| HCT-CI§ | 266 (71%) | 96 (66%) | |
| Low | 168 (63%) | 63 (66%) | |
| Intermediate | 63 (24%) | 18 (19%) | NS |
| High | 35 (13%) | 15 (15%) | |
| IPSS risk | |||
| Low | 29 (8%) | — | <.001 |
| Intermediate-1 | 134 (36%) | — | |
| Intermediate-2 | 157 (42%) | 20 (14%) | |
| High | 54 (14%) | 125 (86%) | |
| IPSS-R risk | |||
| Low | 59 (16%) | — | <.001 |
| Intermediate | 78 (21%) | 11 (8%) | |
| High | 140 (37%) | 67 (46%) | |
| Very high | 97 (26%) | 67 (46%) |
NS, not significant.
All variables were analyzed at the time of transplantation in patients undergoing upfront allogeneic HSCT and at the time of remission-induction chemotherapy in those receiving treatment before transplantation.
Oligoblastic AML included patients affected with RAEB-t according to the FAB classification.
Transfusion dependency was defined as having ≥1 red cell transfusion every 8 weeks over a period of 4 months.10
HCT-CI as defined by Sorror et al.22